Grazia Saturno

Alderley Park
Manchester, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Expression of Concern: Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma.

Expression of Concern: Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma.

Journal: Cancer discovery

Published: December 18, 2025

The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers.

The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: June 15, 2020

Author Correction: Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface.

Author Correction: Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface.

Journal: Nature communications

Published: July 20, 2019

Anti-metastatic Inhibitors of Lysyl Oxidase (LOX): Design and Structure-Activity Relationships.

Anti-metastatic Inhibitors of Lysyl Oxidase (LOX): Design and Structure-Activity Relationships.

Journal: Journal of medicinal chemistry

Published: May 10, 2019

Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma.

Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma.

Journal: Cancer cell

Published: March 16, 2017

Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface.

Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface.

Journal: Nature communications

Published: November 11, 2016

Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma.

Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma.

Journal: Cancer discovery

Published: November 09, 2015

Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy.

Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy.

Journal: EMBO molecular medicine

Published: June 17, 2015

No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients.

No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients.

Journal: Molecular oncology

Published: July 31, 2014

Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.

Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.

Journal: Cancer cell

Published: May 17, 2014

BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling.

BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling.

Journal: Science signaling

Published: March 27, 2014

Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition.

Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 08, 2014

Showing 1-12 of 13

Last Updated: 09/26/2026